August 26, 2015

Genetic Mutation Analysis May Improve Treatment in Multiple Myeloma

Gareth Morgan, M.D., FRCP, FRCPath, Ph.D.

Testing for genetic risk factors may improve myeloma treatments by identifying those at risk for more aggressive disease. This study, published in the Journal of Clinicial Oncology and led by researchers in London, including our own Myeloma Institute Director, Dr. Gareth Morgan, is the first to link genetic mutations in myeloma cells to the chances…

August 14, 2015

My Advice to Myeloma Patients

August 13, 2015

New publication

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

August 5, 2015

Congratulations to Dr. Frits van Rhee on his newest publication

Frits van Rhee, M.D., Ph.D., MRCP, FRCPath

Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”. Be sure to check it out! Read here on Onctotarget